Qualigen signs exclusive license agreement with university of louisville, plans to develop as1411 for treatment of covid-19

Qualigen therapeutics signs exclusive license agreement with university of louisville, plans to develop as1411 for treatment of covid-19.qualigen - has held an exclusive license to as1411 for all fields of use since 2018.qualigen - agreed to pay uofl royalties in low-to-mid-single-digit percentages on as1411 anti-covid-19 product sales using uofl's technology, patents.qualigen - undertook to enter sponsored research agreement with uofl for further in vitro and preclinical animal studies with as1411 against covid-19.
QLGN Ratings Summary
QLGN Quant Ranking